Santhanam: Shows results courtesy of UK NEQAS - three labs, one able to get to 1%; two others at 4%. #MDxEU17
5:14am April 11th 2017 via Hootsuite
Santhanam: For validation/EQA, can you send to many labs? Broad range sample types; working on matched genotypes. cGMP batch rcrd #MDxEU17
5:13am April 11th 2017 via Hootsuite
Santhanam: Offer a linearity panel (8%/4%/2%/1%) shows LOD data for two platforms - MPSS around 3-4%; another provider at 2-4% #MDxEU17
5:12am April 11th 2017 via Hootsuite
Santhanam: Like a dashboard in a car, how can you drive without feedback? At dev stage, confirming known fetal fractions #MDxEU17
5:11am April 11th 2017 via Hootsuite
Santhanam: Thus treated like a patient sample, multiple approaches can be tried out for dev, for validation can perform as designed #MDxEU17
5:10am April 11th 2017 via Hootsuite
Ram Santhanam: Product is trisomic cell lines, fragmented via sonication, encapsulated and blended into synthetic plasma. #MDxEU17
5:09am April 11th 2017 via Hootsuite
Santhanam: SeraCare also produces software to assist in tracking data. https://t.co/ze2LnyXTSx #MDxEU17
Santhanam: Shows var via BioAnalyzer traces of sample prep step. Highly multiplexed assays require multiplexed ref materials #MDxEU17
5:08am April 11th 2017 via Hootsuite
Santhanam: How to move to production; how to get to multi-site comparisons. Shows '15 fig from https://t.co/cun2oK1aG2 Error to 11% #MDxEU17
5:07am April 11th 2017 via Hootsuite
Santhanam: About 80% of assays worldwide use SeraCare materials. Challenges include need to develop assays quickly. How to validate #MDxEU17
5:05am April 11th 2017 via Hootsuite
Santhanam: 30y company history, background in infectious disease. '80s began w/the first seroconversion panel. #MDxEU17
5:04am April 11th 2017 via Hootsuite
Santhanam: Going from biological challenges, now how to make you more successful for assay development, monitoring #MDxEU17
5:03am April 11th 2017 via Hootsuite
Ram Santhanam (SeraCare MA): Expediting NIPT assay development, validation and routine monitoring #MDxEU17
5:02am April 11th 2017 via Hootsuite
Dieguez: Limitations - no ubiquitious biomarker; cells not phenotype indep. Goals of their development: size-based, non-destructive #MDxEU17
4:58am April 11th 2017 via Hootsuite
Dieguez: EMT and poor prognosis - shows several ref's. 2d test, about 450€ per test, needs trained personnel. #MDxEU17
4:56am April 11th 2017 via Hootsuite
Dieguez: Successful but EMT de-differentiation and re-differentiate to form a solid tumor. Thus EpCAM not reliable #MDxEU17
4:55am April 11th 2017 via Hootsuite
Dieguez: CellSearch cutoff is >=5 /7.5mL blood (mBC and mPC); >=3/7.5mL for mCRC. If increases - pt is progressing. #MDxEU17
4:53am April 11th 2017 via Hootsuite
Dieguez: CellSearch (recently sold to Menarini), 7.5mL incubated w/EpCAM Ab, use cytokeratin, DAPI for nucleus, CD45 for WBC #MDxEU17
4:52am April 11th 2017 via Hootsuite
Dieguez: Can see markers of origin and markers of mutation in the same cell; of course rarity a challenge. #MDxEU17
4:51am April 11th 2017 via Hootsuite
Dieguez: Monitoring progression - believe that CTCs have several advantages: living and can proliferate them 'if you are lucky' #MDxEU17
4:50am April 11th 2017 via Hootsuite
Dieguez: In Braga (northern Portugal), gov of Spain and Portugal. Have 40 PI's. Started in '05, '14 new space. 100M € building. #MDxEU17
4:47am April 11th 2017 via Hootsuite
Lorena Dieguez (Iberian Nanotech Lab, PT) Microfluidic isolation of cancer cells from body fluids for early and non-invasive Dx #MDxEU17
4:43am April 11th 2017 via Hootsuite
Q: Is 1:100K the detection rate? Patel: Raw error. Analytical sens is 1:10K, also context dependent #MDxEU17
Patel: #MDxEU17 (FYI: commercialized via company called TwinStrand - GenomeWeb https://t.co/3vqelOzh5u ) requires high conversion efficiency
4:40am April 11th 2017 via Hootsuite
Patel: Deamination causes C-U mutations; oxidation of guanine forms 9-oxo-guanine G-T '12 PNAS duplex https://t.co/jcOiN1w84k #MDxEU17
4:39am April 11th 2017 via Hootsuite
Patel: Technical challenges: Shows interesting bar chart from this '15 ref https://t.co/bWogfxmXUy of the need for broad coverage #MDxEU17
4:37am April 11th 2017 via Hootsuite
Patel: Shows RECIST criteria of tumor burden decline in responders, increase w/ non-responders. #MDxEU17
4:35am April 11th 2017 via Hootsuite
Patel: Faster ctDNA drop in cp to CEA observed. I-O response: 2 pts; responders showing KRAS Q61R drop; non-resp, PIK3CA rises #MDxEU17
4:34am April 11th 2017 via Hootsuite
Patel: 84 y/o F w/rectal ca metastatic to liver, FOLFOX and Avastin chemo w/excellent response, KRAS G12Cys ctDNA drops cp to CEA #MDxEU17
4:32am April 11th 2017 via Hootsuite
Patel: After spiking post-Rx, undetectable 50d post, follow-up 5 months post-Rx no evidence of residual disease #MDxEU17
4:30am April 11th 2017 via Hootsuite
Patel: 75yo Stg I female, adenocarcincoma of rt lung. 2.9x2.5cm tumor, KRAS G13R, showed stereotactic Rx & G13R in copies/mL #MDxEU17
Patel: Claim mean background error rate of <1 in 100K. $20 seq cost per sample. One tube, one PCR, one SPRI bead purification #MDxEU17
4:27am April 11th 2017 via Hootsuite
Patel: Sequencing both top and bottom strands; not as complex a barcoding scheme as SafeSeqS; look at molecular lineage #MDxEU17
4:26am April 11th 2017 via Hootsuite
Patel: Error-suppressed sequencing: multiplexing 60- or 70-fold; sequencing and PCR errors: bidirectional PE for NGS #MDxEU17
4:22am April 11th 2017 via Hootsuite
Patel: Compartments via droplet PCR or BEAMing. NGS-based methods use amplicons or hyb-capture/ligation #MDxEU17
4:18am April 11th 2017 via Hootsuite
Patel: Measuring ctDNA is challenging due to size; methods include mutant enrichment (COLD-PCR, LNA/PNA, ARMS) or compartments #MDxEU17
Patel: Another '14 NEJM https://t.co/vv4InWAmHp Clonal hematopoesis may cause mutations to appear in healthy individuals #MDxEU17
4:17am April 11th 2017 via Hootsuite
Patel: KRAS mutants exist in pre-cancerous lesions in lung tissue, for example. No good answer. '14 NEJM https://t.co/LhrEDOm2VW #MDxEU17
4:15am April 11th 2017 via Hootsuite
Patel: Do early-stage tumors release sufficient DNA? Are the same muts found in healthy individuals? #MDxEU17
4:14am April 11th 2017 via Hootsuite
Patel: Background error correction must be employed, as well as broad mutation coverage; biological challenges remain #MDxEU17
4:13am April 11th 2017 via Hootsuite
Patel: Tumor-derived biomarker portion is in the context of (relatively) high background; ctDNA is, in principle, only frm tumor #MDxEU17
4:11am April 11th 2017 via Hootsuite
Patel: His focus today - treatment response assessment, and early detection. Protein biomarkers - PSA for everyone is non-zero #MDxEU17
4:10am April 11th 2017 via Hootsuite
Patel: Expertise in therapeutic radiology. Non-invasive genotyping, resistance mutations, residual disease, disease recurr... #MDxEU17
4:09am April 11th 2017 via Hootsuite
Abhijit Patel (Yale Univ CT) Early detection using cfDNA: promise and challenges #MDxEU17
4:05am April 11th 2017 via Hootsuite
Helen Winter (Univ Oxford UK) Into at #MDxEU17 - two themes, early detection, and pt selection/stratification. Real challenge: translation
RT @NatureNews: The DIY electronics transforming research, from Raspberry Pi to Arduino: https://t.co/X5zauDxCbz https://t.co/Uza0aUsLC2
4:02am April 11th 2017 via Hootsuite
@larshaakon Hi - this was only her summary of #AACR17 likely from this plenary https://t.co/2sELB2zsN4 which I didn… https://t.co/WgO0MvgiKo
11:11am April 10th 2017 via Hootsuite in reply to larshaakon
Bernal: Onto proteomic markers; shows volcano plot to find statistical sig by magnitude of change, in serial in-labor plasma #MDxEU17
11:04am April 10th 2017 via Hootsuite
Bernal: There is a connection between infection and pre-term birth, but prostaglandin as a surrogate marker may be a red herring #MDxEU17
Bernal: #MDxEU17 Early excitement about accurate tests https://t.co/KhTiqGhAbi all have same problems of low PPV
10:58am April 10th 2017 via Hootsuite
